Search the Newsreel

Immunome, Inc. Revenue Breakdown – BOATS:IMNM

Immunome, Inc. (IMNM) generated $6.94 million in revenue last year, primarily from its Targeted Oncology Therapies segment. This figure is down from $9.04 million in the previous year. The United States was the greatest contributor to their revenue, accounting for the entire $6.94 million.

Immunome Inc (IMNM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Immunome Inc (IMNM) stock, focusing on its dividend and stock split history. It indicates that Immunome Inc has not distributed any dividends over the past five years. The page also presents current stock data including market cap and …

IMNM|Immunome Inc|Price:22.220|Chg%:+0.210

This article provides a detailed financial overview of Immunome Inc (IMNM), including its stock price, market cap, and key financial indicators. It presents quarterly and annual data for income statements, balance sheets, and cash flow statements, offering insights into the company's revenue, net profit, …

Immunome, Inc. (IMNM) Stock Analysis: A 62% Potential Upside In The Biotech Arena

Immunome, Inc. (IMNM) is a US-based biotech firm focusing on antibody-drug conjugates and oncology therapeutics, with a market capitalization of $2.49 billion. Despite current financial challenges like negative EPS and no reported revenue growth, analysts project a 62.51% upside potential with an average target …

Immunome Inc. (IMNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock Reaction - Share Dilution Risk

Immunome, Inc. (IMNM) stock price, news, quote and history

This article provides a comprehensive overview of Immunome, Inc. (IMNM) stock, including its current price, key financial metrics, performance data, and analyst ratings. It details the company's biotechnology focus, pipeline of antibody-drug conjugates and oncology therapeutics, and lists comparative companies in the biotechnology industry.

LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40

LifeSci Capital has reiterated its Buy rating for Immunome (IMNM.US) and maintained a target price of $40. This indicates continued confidence in the company's stock performance from the analyst firm.

IMNM Reiterates by Wedbush -- Price Target Maintained at $31

Wedbush analyst David Nierengarten has maintained an "Outperform" rating for Immunome (IMNM) with an unchanged price target of $31.00. Despite this positive analyst rating, Immunome is deemed significantly overvalued by GuruFocus, trading at $22.29 against a GF Value™ of $1.68, indicating a 1226.8% overvaluation. …

Immunome doses first patient in IM-3050 cancer therapy trial

Immunome Inc. has dosed the first patient in a Phase 1 trial for IM-3050, an investigational radioligand therapy targeting advanced solid tumors by delivering radioactive lutetium-177 to FAP-expressing cells. The company's shares have surged, and analyst sentiment remains bullish with upwardly revised price targets. …

IMNM Q1 2026 Earnings: EPS Surprises to the Upside but No Revenue; Shares Edge Lower

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Immunome, Inc. has announced the dosing of the first patient in its Phase 1 trial for IM-3050, a FAP-targeted radioligand therapy. This therapy is designed to deliver radioactive lutetium-177 directly to fibroblast activation protein (FAP)-expressing cells in patients with advanced solid tumors. The trial …

Price-Driven Insight from (IMNM) for Rule-Based Strategy

This article provides a price-driven insight for Immunome Inc. (NASDAQ: IMNM), highlighting a weak near-term sentiment but a strong mid to long-term outlook. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and offers a …

Immunome (IMNM) NDA Acceptance Puts Valuation Back In Focus

Immunome (IMNM) is gaining attention after the FDA accepted its New Drug Application for varegacestat, an oral therapy for desmoid tumors, backed by positive Phase 3 trial data. While the stock's price-to-book ratio of 4.3x presents mixed signals compared to peers and the broader …

Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data

Immunome's stock dropped by 8.2% despite the FDA accepting its New Drug Application for varegacestat, an oral treatment for desmoid tumors, based on strong Phase 3 data. This acceptance provides a clear regulatory timeline but the company still faces financial risks due to its …

Immunome Inc. (IMNM) Rallies 2.35%, Approaching Key Resistance at $20.14 - Leveraged ETF Flow

Immunome (IMNM) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline - Earnings Growth Analysis

Immunome Inc. (IMNM) Q1 2026 Earnings: Narrower Loss Beats Estimates; Stock Gains Modestly - Margin Guidance

Immunome Desmoid Tumor Data And NDA Plan Test Growth Expectations

Analyst Expectations For Immunome's Future

Immunome (IMNM) Earnings Date and Reports 2026